|
1
|
CAPRIE Steering Committee: A randomised,
blinded, trial of clopidogrel versus aspirin in patients at risk of
ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet.
348:1329–1339. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yusuf S, Zhao F, Mehta SR, Chrolavicius S,
Tognoni G and Fox KK: Clopidogrel in Unstable Angina to Prevent
Recurrent Events Trial Investigators: Effects of clopidogrel in
addition to aspirin in patients with acute coronary syndromes
without ST-segment elevation. N Engl J Med. 345:494–502. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mehta SR, Yusuf S, Peters RJ, Bertrand ME,
Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F,
Chrolavicius S, et al: Effects of pretreatment with clopidogrel and
aspirin followed by long-term therapy in patients undergoing
percutaneous coronary intervention: The PCI-CURE study. Lancet.
358:527–533. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuliczkowski W, Witkowski A, Polonski L,
Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski
J, Gorski J, et al: Interindividual variability in the response to
oral antiplatelet drugs: A position paper of the working group on
antiplatelet drugs resistance appointed by the section of
cardiovascular interventions of the polish cardiac society,
endorsed by the workinggroup on thrombosis of the european society
of cardiology. Eur Heart J. 30:426–435. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Angiolillo DJ, Fernandez-Ortiz A, Bernardo
E, Alfonso F, Macaya C, Bass TA and Costa MA: Variability in
individual responsiveness to clopidogrel: Clinical implications,
management, and future perspectives. J Am Coll Cardiol.
49:1505–1516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang TH, Bhatt DL and Topol EJ: Aspirin
and clopidogrel resistance: An emerging clinical entity. Eur Heart
J. 27:647–654. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Al-Azzam SI, Alzoubi KH, Khabour OF,
Nusair MB, Al-Hadidi H, Awidi A and Saleh A: Factors that
contribute to clopidogrel resistance in cardiovascular disease
patients: Environmental and genetic approach. Int J Clin Pharmacol
Ther. 51:179–186. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koh YY, Kim HH, Choi DH, Lee YM, Ki YJ,
Kang SH, Park G, Chung JW, Chang KS and Hong SP: Relation between
the change in mean platelet volume and clopidogrel resistance in
patients undergoing percutaneous coronary intervention. Curr Vasc
Pharmacol. 687–693. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bliden KP, Dichiara J, Lawal L, Singla A,
Antonino MJ, Baker BA, Bailey WL, Tantry US and Gurbel PA: The
association of cigarette smoking with enhanced platelet inhibition
by clopidogrel. J Am Coll Cardiol. 52:531–533. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Geiger J, Brich J, Hönig-Liedl P,
Eigenthaler M, Schanzenbächer P, Herbert JM and Walter U: Specific
impairment of human platelet P2Y(AC) ADP receptor-mediated
signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb
Vasc Biol. 19:2007–2011. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bonello L, Paganelli F, Arpin-Bornet M,
Auquier P, Sampol J, Dignat-George F, Barragan P and Camoin-Jau L:
Vasodilator-stimulated phosphoprotein phosphorylation analysis
prior to percutaneous coronary intervention for exclusion of
postprocedural major adverse cardiovascular events. J Thromb
Haemost. 5:1630–1636. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cotton JM, Worrall AM, Hobson AR,
Smallwood A, Amoah V, Dunmore S, Nevill AM, Raghuraman RP, Vickers
J and Curzen N: Individualised assessment of response to
clopidogrel in patients presenting with acute coronary syndromes: A
role for short thrombelastography? Cardiovasc Ther. 28:139–146.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nagalla S, Shaw C, Kong X, Kondkar AA,
Edelstein LC, Ma L, Chen J, McKnight GS, López JA, Yang L, et al:
Platelet microRNA-mRNA coexpression profiles correlate with
platelet reactivity. Blood. 117:5189–5197. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Plé H, Landry P, Benham A, Coarfa C,
Gunaratne PH and Provost P: The repertoire and features of human
platelet microRNAs. PLoS One. 7:e507462012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duan X, Zhan Q, Song B, Zeng S, Zhou J,
Long Y, Lu J, Li Z, Yuan M, Chen X, et al: Detection of platelet
microRNA expression in patients with diabetes mellitus with or
without ischemic stroke. J Diabetes Complications. 28:705–710.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang K, Yuan Y, Cho JH, McClarty S, Baxter
D and Galas DJ: Comparing the MicroRNA spectrum between serum and
plasma. PLoS One. 7:e415612012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Landry P, Plante I, Ouellet DL, Perron MP,
Rousseau G and Provost P: Existence of a microRNA pathway in
anucleate platelets. Nat Struct Mol Biol. 16:961–966. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kondkar AA, Bray MS, Leal SM, Nagalla S,
Liu DJ, Jin Y, Dong JF, Ren Q, Whiteheart SW, Shaw C and Bray PF:
VAMP8/endobrevin is overexpressed in hyperreactive human platelets:
Suggested role for platelet microRNA. J Thromb Haemost. 8:369–378.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Girardot M, Pecquet C, Boukour S, Knoops
L, Ferrant A, Vainchenker W, Giraudier S and Constantinescu SN:
miR-28 is a thrombopoietin receptor targeting microRNA detected in
a fraction of myeloproliferative neoplasm patient platelets. Blood.
116:437–445. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aleil B, Ravanat C, Cazenave JP, Rochoux
G, Heitz A and Gachet C: Flow cytometric analysis of intraplatelet
VASP phosphorylation for the detection of clopidogrel resistance in
patients with ischemic cardiovascular diseases. J Thromb Haemost.
3:85–92. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dweep H, Gretz N and Sticht C: miRWalk
database for miRNA-target interactions. Methods Mol Biol.
1182:289–305. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cuisset T, Frere C, Quilici J, Gaborit B,
Castelli C, Poyet R, Bali L, Morange PE, Alessi MC and Bonnet JL:
Predictive values of post-treatment adenosine diphosphate-induced
aggregation and vasodilator-stimulated phosphoprotein index for
stent thrombosis after acute coronary syndrome in
clopidogrel-treated patients. Am J Cardiol. 104:1078–1082. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nguyen TA, Diodati JG and Pharand C:
Resistance to clopidogrel: A review of the evidence. J Am Coll
Cardiol. 45:1157–1164. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Spokoyny I, Barazangi N, Jaramillo V, Rose
J, Chen C, Wong C and Tong D: Reduced clopidogrel metabolism in a
multiethnic population: Prevalence and rates of recurrent
cerebrovascular events. J Stroke Cerebrovasc Dis. 23:694–698. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gurbel PA, Bliden KP, Hiatt B and O'Connor
CM: Clopidogrel for coronary stenting: Response variability, drug
resistance, and the effect of pretreatment platelet reactivity.
Circulation. 107:2908–2913. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jy W, Horstman LL, Park H, Mao WW, Valant
P and Ahn YS: Platelet aggregates as markers of platelet
activation: Characterization of flow cytometric method suitable for
clinical applications. Am J Hematol. 57:33–42. 1988. View Article : Google Scholar
|
|
28
|
Satoh K, Yatomi Y and Ozaki Y: Detection
method for platelet activation markers. Rinsho Byori. 50:773–778.
2002.(In Japanese). PubMed/NCBI
|
|
29
|
Bonello L, Tantry US, Marcucci R, Blindt
R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP,
Cuisset T, et al: Consensus and future directions on the definition
of high on-treatment platelet reactivity to adenosine diphosphate.
J Am Coll Cardiol. 56:919–933. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Morel O, Viellard C, Faure A, Jesel L,
Ohlmann P, Desprez D, Chauvin M, Roul G, Grunebaum L and Bareiss P:
Platelet responsiveness to clopidogrel in patients with coronary
syndrome. Comparison of platelet aggregation induced by ADP and
flow cytometric analysis of intraplatelet VASP phosphorylation. Ann
Cardiol Angeiol (Paris). 56:21–29. 2007.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim KA, Park PW, Hong SJ and Park JY: The
effect of CYP2C19 polymorphism on the pharmacokinetics and
pharmacodynamics of clopidogrel: A possible mechanism for
clopidogrel resistance. Clin Pharmacol Ther. 84:236–242. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Notarangelo MF, Bontardelli F and Merlini
PA: Genetic and nongenetic factors influencing the response to
clopidogrel. J Cardiovasc Med (Hagerstown). 14(Suppl 1): S1–S7.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Berezikov E, Cuppen E and Plasterk RH:
Approaches to microRNA discovery. Nat Genet. 38(Suppl): S2–S7.
2006. View
Article : Google Scholar : PubMed/NCBI
|
